MTBDRplus在初治2个月末涂阳肺结核治疗中的应用

发布时间：2018-03-17 04:14

本文选题：结核　切入点：肺　出处：《重庆医学》2016年34期 　论文类型：期刊论文

【摘要】：目的运用分子线性探针技术(MTBDRplus)对2个月末涂片阳性的初治肺结核患者进行快速耐药检测及个体化治疗指导,并观察其预后。方法选择基线及2个月末痰涂片仍为阳性的初治肺结核患者随机分两组,分别予以传统直接观察(或面视)下的短程化疗(Directly Observed Treatment+short course chemotherapy,DOTs)方案及分子药敏指导治疗,并比较预后。结果在分子药敏指导治疗组中成功率,完全敏感的为74.4%,单耐异烟肼为87.5%,单耐利福平100.0%,耐多药结核75.0%;DOTs方案组中,成功率为单耐异烟肼25.0%,单耐利福平耐和耐多药结核均为0.0%。两组预后χ~2分析显示差异有统计学意义(P=0.044)。结论 MTBDRplus应用在2个月末涂阳初治肺结核患者中可改善预后。
[Abstract]:Objective to apply molecular linear probe technique to detect drug resistance in two months smear-positive patients with primary pulmonary tuberculosis and to guide individual treatment. Methods the patients with primary pulmonary tuberculosis who were still positive for sputum smear at baseline and at the end of 2 months were randomly divided into two groups. The patients were treated with direct Observed Treatment short course chemotherapy under traditional direct observation (or face view) and molecular chemosensitivity, and the prognosis was compared. Results the success rate in the treatment group guided by molecular drug sensitivity was higher than that in the control group. Total sensitivity was 74.4, isoniazid was 87.5, rifampicin was 100.0, MDR-TB was 75.0 in DOTs group, The success rate was 25. 0% for isoniazid, 0. 0 for rifampicin resistance and 0. 0 for multidrug resistant tuberculosis. 蠂 2 analysis showed that there was a significant difference in prognosis between the two groups. Conclusion MTBDRplus can improve the prognosis of pulmonary tuberculosis at the end of 2 months.
【作者单位】：西南医科大学附属医院感染科;浙江诸暨市人民医院感染科;杭州市疾病预防控制中心;复旦大学附属华山医院感染科;
【基金】：四川省泸州市科技局资助项目[2014-s-45(7/12)] 西南医科大学附属第一医院博士基金(14047)
【分类号】：R521

【相似文献】